Placeholder Banner

BIO Comments to the FDA on the Agency’s Updated Guidance on PREA and BPCA

July 17, 2023

BIO provides general comments and recommendations on FDA’s Pediatric Drug Development Under the Pediatric Research Equity Act and the Best Pharmaceuticals for Children Act (Docket No. FDA-2005-D-0460-0008)

Download Full Comments Below
BIO Comment Letter - FDA-2005-D-0460-0008 - Scientific Considerations PREABCPA_FINA
Discover More
BIO Board Vice Chair and CEO of Amicus Therapeutics testified that the drug price controls in the Inflation Reduction Act harm drug research and development.
BIO joined with other groups in writing House and Senate Agriculture Committee leaders in support of agricultural research (FFAR) funding in the farm bill.